Application of patient population-derived pharmacokinetic-pharmacodynamic relationships to tigecycline breakpoint determination for staphylococci and streptococci

Diagnostic Microbiology and Infectious Disease

Volumn 63, Issue 2, 2009, Pages 155-159

  Ambrose, Paul G ^a   Meagher, Alison K ^b   Passarell, Julie A ^b   Van Wart, Scott A ^b   Cirincione, Brenda B ^b   Bhavnani, Sujata M ^a   Ellis Grosse, Evelyn ^c  

^a ORDWAY RESEARCH INSTITUTE   (United States)

^b Albany Medical College   (United States)

^c PFIZER INC   (United States)

Author keywords

Staphylococcus aureus; Streptococci; Susceptibility breakpoint

Indexed keywords

TIGECYCLINE;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PHARMACODYNAMICS; PRIORITY JOURNAL; SIMULATION; SKIN INFECTION; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS; STREPTOCOCCUS INFECTION;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; COMPUTER SIMULATION; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; MODELS, BIOLOGICAL; MODELS, STATISTICAL; MONTE CARLO METHOD; REGRESSION ANALYSIS; ROC CURVE; SKIN DISEASES, BACTERIAL; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS;

EID: 58249141147     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.10.011     Document Type: Article

References (19)

1. Ambrose P.G. Monte Carlo simulation in the evaluation of susceptibility breakpoints: predicting the future. Pharmacotherapy 25 (2006) 129-134
2. Ambrose P.G., and Grasela D.M. The use of Monte Carlo simulation to examine pharmacodynamic variance of drugs: fluoroquinolone pharmacodynamics against Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 38 (2000) 151-157
3. Ambrose P.G., Grasela D.M., Grasela T.H., Passarell J., Mayer H.B., and Pierce P.F. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob. Agents Chemother. 45 (2001) 2793-2797
4. Ambrose P.G., Bhavnani S.M., and Jones R.N. Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases: report from the ARREST Program. Antimicrob. Agents Chemother. 47 (2003) 1643-1646
5. Booker B.M., Smith P.F., Forrest A., Bullock J., Kelchlin P., Bhavnani S.M., and Ambrose P.G. Pharmacokinetic and pharmacodynamic characterization of gatifloxacin against Salmonella Typhi in an in vitro infection model. Antimicrob. Agents Chemother. 49 (2005) 1775-1781
6. Craig W.A., and Andes D.R. In vivo pharmacodynamic activity of ceftriaxone against viridans streptococci: implications for susceptibility breakpoints. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago Illinois, December 22nd to 25th. Abstract A-2089 (2001)
7. Doern G.V., Jones R.N., Pfaller M.A., Kugler K.C., and Beach M.L. Bacterial pathogens isolated from patients with skin and soft tissue infections; frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program. Diagn. Microbiol. Infect. Dis. 34 (1999) 65-72
8. Drusano G.L., Preston S.L., Hardalo C., Hare R., Banfield C., Andes D., Vesga O., and Craig W.A. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrob. Agents Chemother. 45 (2001) 13-22
9. Dudley M.N., and Ambrose P.G. Pharmacodynamics in the study of drug resistance and setting of in vitro susceptibility breakpoints: ready for prime time. Curr. Opin. Microbiol. 3 (2000) 515-521
10. Forrest A., Chodash S., Amantea M.A., Collins D.A., and Schentag J.J. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J. Antimicrob. Chermother. 40 Suppl. A (1997) 45-57
11. Kuti J.L., and Nicolau D.P. Making the most of surveillance studies: summary of the OPTAMA Program. Diagn. Microbiol. Infect. Dis. 53 (2005) 281-287
12. Kuti J.L., Horowitz S., Nightingale C.H., and Nicolau D.P. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem. Pharmacotherapy 25 (2005) 935-941
13. Meagher A.K., Passarell J.A., Cirincione B.B., Van Wart S.A., Liolios K., Babinchak T., Ellis-Grosse E.J., and Ambrose P.G. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin structure infections. Antimicrob. Agents Chemother. 51 (2007) 1939-1945
14. Nichols R.L. Optimal treatment of complicated skin and skin structure infections. J. Antimicrob. Chemother. 44 Suppl. A (1999) 19-23
15. Ong C.T., Kuti J.L., Nicolau D.P., and OPTAMA Program. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program. Surg. Infect. 6 (2005) 419-426
16. Preston S.L., Drusano G.L., Berman A.L., Fowler C.L., Chow A.T., Dornseif B., Reichi V., Natarajan J., Wong W.A., and Corrado M. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 279 (1997) 125-129
17. Talbot G.H., Bradley J., Edwards Jr. J.E., Gilbert D., Scheld M., Bartlett J.G., and Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin. Infect. Dis. 42 (2006) 657-668
18. van Ogtrop M.L., Andes D., Stamstad T.J., Conklin B., Weiss W.J., Craig W.A., and Vesga O. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 44 (2000) 943-949
19. Van Wart S.A., Owen J.S., Ludwig E.A., Meagher A.K., Korth-Bradley J.M., and Cirincione B.B. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin-structure infections. Antimicrob. Agents Chemother. 50 (2006) 3701-3707